References in periodicals archive ?
Under the terms of the deal, BMS will sell the assets of Onglyza, Kombiglyze XR/Komboglyze, dapagliflozirt, Bye tta, By-dureon, Symlin and metreleptin.
Most recently the agency approved Amylin Pharmaceuticals' injectable diabetes drug Symlin on the condition that it not be advertised directly to consumers or in medical journals for a year.
21 June 2011 - US-based biopharmaceutical company Amylin Pharmaceuticals Inc (NASDAQ: AMLN) said yesterday that it will present data for its two first-in-class diabetes drugs, BYETTA (exenatide) injection and SYMLIN (pramlintide acetate) injection, and its investigational diabetes drug candidates BYDUREON and exenatide once monthly at the 71st Scientific Sessions of the American Diabetes Association (ADA) being held in San Diego, 24-28 June.
Symlin is approved for use in patients with type 2 or type 1 diabetes who use mealtime insulin and need to improve glucose control.
A black box warning highlights the increased risk of insulin-induced severe hypoglycemia associated with Symlin, particularly in type 1 diabetics.
The company's lead drug candidate, Symlin, is under review by the FDA as a potential treatment for diabetes patients who use insulin.
Pramlintide, which is marketed by Amylin under the trade name Symlin, is a synthetic analogue of human amylin, a naturally occurring neuroendocrine hormone that is secreted with insulin by pancreatic B cells and is also deficient in diabetes.
The company is seeking FDA approval of the injectable compound, called Symlin, for use before meals in concert with insulin in patients with type 1 or type 2 diabetes.
a development pharmaceutical firm, is testing Symlin and is preparing regulatory submissions for the middle of this year for Type 1 and Type 2 diabetes.
GlobalData's pharmaceuticals report, Symlin (Type 2 Diabetes) - Analysis and Forecasts to 2020 provides Nesina sales estimates for US.
Recognizing the important role it plays in helping patients control blood sugar at mealtime, ADA/EASD included SYMLIN in their new position statement on the treatment of hyperglycemia.
Amylin will highlight data from 13 abstracts, offering new insights into the clinical utility of BYDUREON, BYETTA and SYMLIN, as well as continued research into the exenatide pipeline.